These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 37658934)

  • 41. Is it possible to extend the dose interval of canakinumab treatment in children with familial Mediterranean fever? PeRA group experience.
    Kavrul Kayaalp G; Çağlayan Ş; Demirkan FG; Guliyeva V; Otar Yener G; Öztürk K; Demir F; Özdel S; Çakan M; Sönmez HE; Sözeri B; Aktay Ayaz N
    Pediatr Rheumatol Online J; 2023 Nov; 21(1):140. PubMed ID: 37996934
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Growth in familial mediterranean fever: effect of attack rate, genotype and colchicine treatment.
    Türkmen M; Soylu OB; Kasap B; Güneş S; Tüfekçi O; Soylu A; Erçal D; Kavukçu S
    J Pediatr Endocrinol Metab; 2008 Aug; 21(8):789-92. PubMed ID: 18825879
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Down-regulated Th17 cells in a patient with familial Mediterranean fever associated with amyloid A amyloidosis in the treatment of canakinumab.
    Goto T; Miyazaki Y; Nakayamada S; Shiraishi N; Yoshinaga T; Tanaka Y; Nakamura T
    Mod Rheumatol Case Rep; 2023 Jan; 7(1):237-242. PubMed ID: 35349715
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Approach to the patients with inadequate response to colchicine in familial Mediterranean fever.
    Gül A
    Best Pract Res Clin Rheumatol; 2016 Apr; 30(2):296-303. PubMed ID: 27886801
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Outcomes of Canakinumab Treatment in Recipients of Kidney Transplant With Familial Mediterranean Fever: A Case Series.
    Sendogan DO; Saritas H; Kumru G; Eyupoglu S; Sadioglu RE; Tuzuner A; Sengul S; Keven K
    Transplant Proc; 2019 Sep; 51(7):2292-2294. PubMed ID: 31400972
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Familial Mediterranean fever in childhood: a single-center experience.
    Barut K; Sahin S; Adrovic A; Sinoplu AB; Yucel G; Pamuk G; Aydın AK; Dasdemir S; Turanlı ET; Buyru N; Kasapcopur O
    Rheumatol Int; 2018 Jan; 38(1):67-74. PubMed ID: 28828621
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Canakinumab treatment in kidney transplant recipients with AA amyloidosis due to familial Mediterranean fever.
    Trabulus S; Korkmaz M; Kaya E; Seyahi N
    Clin Transplant; 2018 Aug; 32(8):e13345. PubMed ID: 29981275
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Mesothelioma in Familial Mediterranean Fever With Colchicine Intolerance: A Case Report and Literature Review.
    Talerico R; Cardillo C; De Vito F; Schinzari F; Soldato M; Giustiniani MC; Verrecchia E; Manna R
    Front Immunol; 2020; 11():889. PubMed ID: 32477360
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Interleukin-1 targeting treatment in familial Mediterranean fever: an experience of pediatric patients.
    Başaran Ö; Uncu N; Çelikel BA; Taktak A; Gür G; Cakar N
    Mod Rheumatol; 2015 Jul; 25(4):621-4. PubMed ID: 25528863
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effectiveness of Canakinumab Treatment in Colchicine Resistant Familial Mediterranean Fever Cases.
    Yücel BB; Aydog O; Nalcacioglu H; Yılmaz A
    Front Pediatr; 2021; 9():710501. PubMed ID: 34568239
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Interleukin-1 targeting drugs in familial Mediterranean fever: a case series and a review of the literature.
    Meinzer U; Quartier P; Alexandra JF; Hentgen V; Retornaz F; Koné-Paut I
    Semin Arthritis Rheum; 2011 Oct; 41(2):265-71. PubMed ID: 21277619
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Growth and IGF-1 levels of children with familial Mediterranean fever on colchicine treatment.
    Savgan-Gürol E; Kasapçopur O; Hatemi S; Ercan O; Caliskan S; Sever L; Ozdogan H; Arisoy N
    Clin Exp Rheumatol; 2001; 19(5 Suppl 24):S72-5. PubMed ID: 11760406
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The efficacy of anti- IL-1 treatment in three patients with coexisting familial Mediterranean fever and multiple sclerosis.
    Ozdogan H; Ugurlu S; Uygunoglu U; Tutuncu M; Gul A; Akman G; Siva A
    Mult Scler Relat Disord; 2020 Oct; 45():102332. PubMed ID: 32645635
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Interventions for reducing inflammation in familial Mediterranean fever.
    Wu B; Xu T; Li Y; Yin X
    Cochrane Database Syst Rev; 2018 Oct; 10(10):CD010893. PubMed ID: 30338514
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Canakinumab treatment real world evidence in 3 monogenic periodic fever syndromes in 2009-2022: an interim analysis using the French JIR cohort database.
    Koné-Paut I; Georgin-Lavialle S; Belot A; Jover M; Pouriel M; Lacoin L; Pillet P; Hentgen V
    Arthritis Res Ther; 2024 Apr; 26(1):80. PubMed ID: 38589954
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Nationwide Experience With Off-Label Use of Interleukin-1 Targeting Treatment in Familial Mediterranean Fever Patients.
    Akar S; Cetin P; Kalyoncu U; Karadag O; Sari I; Cınar M; Yilmaz S; Onat AM; Kisacik B; Erden A; Balkarli A; Kucuksahin O; Oner SY; Senel S; Tufan A; Direskeneli H; Oksuz F; Pehlivan Y; Bayindir O; Keser G; Aksu K; Omma A; Kasifoglu T; Unal AU; Yildiz F; Balci MA; Yavuz S; Erten S; Ozgen M; Sayarlıoglu M; Dogru A; Yildirim G; Oner FA; Tezcan ME; Pamuk ON; Onen F
    Arthritis Care Res (Hoboken); 2018 Jul; 70(7):1090-1094. PubMed ID: 28992387
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effectiveness of Colchicine or Canakinumab in Japanese Patients with Familial Mediterranean Fever: A Single-Center Study.
    Yoshida S; Sumichika Y; Saito K; Matsumoto H; Temmoku J; Fujita Y; Matsuoka N; Asano T; Sato S; Migita K
    J Clin Med; 2023 Sep; 12(19):. PubMed ID: 37834916
    [No Abstract]   [Full Text] [Related]  

  • 58. Baseline renal functions predict the effect of canakinumab on regression of proteinuria in patients with familial Mediterranean fever.
    Yildirim T; Yilmaz R; Saglam A; Uzerk-Kibar M; Jabrayilov J; Erdem Y
    Nefrologia (Engl Ed); 2021; 41(6):632-639. PubMed ID: 36165153
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Arterial stiffness in Familial Mediterranean Fever: correlations with disease-related parameters and colchicine treatment.
    Sgouropoulou V; Stabouli S; Trachana M
    Clin Rheumatol; 2019 Sep; 38(9):2577-2584. PubMed ID: 31127463
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Treatment of familial mediterranean fever with canakinumab in patients who are unresponsive to colchicine.
    Berdeli A; Şenol Ö; Talay G
    Eur J Rheumatol; 2019 Apr; 6(2):85-88. PubMed ID: 31365342
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.